SNOW has just cleared its August 26 earnings hurdle, and the immediate read is bullish — analysts are racing targets higher, shorts have been unwinding for weeks, and the options defensive wall that dominated pre-earnings coverage has largely served its purpose.
The analyst response to the print has been the week's clearest signal. Every firm that updated in the past seven days moved higher, and none cut ratings. Citigroup lifted its target to $395 this morning. BofA matched that level earlier in the week, while UBS went furthest at $425. Baird, Benchmark, Mizuho, TD Cowen, Truist, and Jefferies all raised targets into the $350–$385 range — a rare case of unanimous directional conviction across more than ten desks inside a single week. The consensus mean target now sits near $327, though the cluster of fresh estimates well above $350 suggests that figure will migrate higher quickly as more firms update. Against a $317 closing price, the bull case — anchored in AI adoption, expanding platform utility, and forward EPS estimates that have climbed more than 900% year-on-year — is landing with the Street in a way it wasn't six months ago.
The positioning picture has shifted meaningfully since the defensive pre-earnings setup. Short interest has fallen to 5.4% of free float, down 4.4% on the week and nearly 19% over the past month — a sustained unwind from around 23 million shares short in mid-July to roughly 18.2 million now. Borrow costs remain low at 0.46%, up about 13% on the week but still well within normal territory. Availability is extremely loose at nearly 2,000% — around eleven shares available to borrow for every one currently lent out, the most relaxed the lending market has been all year. That combination — falling short interest, cheap borrow, and abundant availability — describes a market where the short thesis is quietly being abandoned rather than aggressively built. The PCR that hit a 52-week high of 0.928 on earnings day, nearly four standard deviations above its 20-day average, was the classic pre-event hedge. Whether that protection gets unwound quickly will depend on how the print is received across the next few sessions.
Chairman Frank Slootman's selling deserves attention on its own terms. He sold approximately $15.7 million across multiple tranches on August 18-19, just ahead of earnings — the largest concentration of insider disposals visible in the recent data window. The net 90-day insider position, however, is a net positive of around 430,000 shares worth roughly $140 million, suggesting the broader insider picture is not uniformly bearish. Slootman's sales are almost certainly plan-driven, but their timing — into a stock that had already rallied 18% in a month — is worth noting. T. Rowe Price added 5.7 million shares as of June 30, the largest institutional increase among top holders. BlackRock holds over 9% and added 3.4 million shares in July. The ownership base is building, not thinning.
The earnings history adds useful context. The prior print on May 27 delivered a single-day move of 34.7%, and the stock held most of that five days later. An earlier event in June produced a 13.9% decline. The asymmetry of those outcomes — one dramatic upside, one sharp reversal — reflects how binary SNOW reactions can be. The stock's 18% one-month gain into this print meant expectations were elevated going in, which is precisely what the PCR extreme was pricing.
What to watch now is whether the analyst target upgrades translate into fresh institutional accumulation over the next few weeks, and whether the PCR normalises back toward its 0.80 mean as the earnings overhang clears — or stays elevated if the guidance or commentary introduces new doubts about the pace of AI revenue conversion.
See the live data behind this article on ORTEX.
Open SNOW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
